Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorThomson, David J.
dc.contributor.authorPalma, David
dc.contributor.authorGuckenberger, Matthias
dc.contributor.authorBalermpas, Panagiotis
dc.contributor.authorBeitler, Jonathan J.
dc.contributor.authorBlanchard, Pierre
dc.contributor.authorGiralt López de Sagredo, Jordi
dc.date.accessioned2021-10-22T09:00:29Z
dc.date.available2021-10-22T09:00:29Z
dc.date.issued2020-07-15
dc.identifier.citationThomson DJ, Palma D, Guckenberger M, Balermpas P, Beitler JJ, Blanchard P, et al. Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):618–27.
dc.identifier.issn0360-3016
dc.identifier.urihttp://hdl.handle.net/11351/6444
dc.descriptionHead and Neck Cancer; Radiation Therapy; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV
dc.description.abstractPurpose Because of the unprecedented disruption of health care services caused by the COVID-19 pandemic, the American Society of Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) identified an urgent need to issue practice recommendations for radiation oncologists treating head and neck cancer (HNC) in a time of limited resources and heightened risk for patients and staff. Methods and Materials A panel of international experts from ASTRO, ESTRO, and select Asia-Pacific countries completed a modified rapid Delphi process. Topics and questions were presented to the group, and subsequent questions were developed from iterative feedback. Each survey was open online for 24 hours, and successive rounds started within 24 hours of the previous round. The chosen cutoffs for strong agreement (≥80%) and agreement (≥66%) were extrapolated from the RAND methodology. Two pandemic scenarios, early (risk mitigation) and late (severely reduced radiation therapy resources), were evaluated. The panel developed treatment recommendations for 5 HNC cases. Results In total, 29 of 31 of those invited (94%) accepted, and after a replacement 30 of 30 completed all 3 surveys (100% response rate). There was agreement or strong agreement across a number of practice areas, including treatment prioritization, whether to delay initiation or interrupt radiation therapy for intercurrent SARS-CoV-2 infection, approaches to treatment (radiation dose-fractionation schedules and use of chemotherapy in each pandemic scenario), management of surgical cases in event of operating room closures, and recommended adjustments to outpatient clinic appointments and supportive care. Conclusions This urgent practice recommendation was issued in the knowledge of the very difficult circumstances in which our patients find themselves at present, navigating strained health care systems functioning with limited resources and at heightened risk to their health during the COVID-19 pandemic. The aim of this consensus statement is to ensure high-quality HNC treatments continue, to save lives and for symptomatic benefit.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesInternational Journal of Radiation Oncology, Biology, Physics;107(4)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPandèmia de COVID-19, 2020-
dc.subjectCap - Càncer - Radioteràpia
dc.subjectColl - Càncer - Radioteràpia
dc.subject.meshPandemics
dc.subject.meshHead and Neck Neoplasms
dc.subject.mesh/radiotherapy
dc.subject.meshCoronavirus Infections
dc.titlePractice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ijrobp.2020.04.016
dc.subject.decspandemias
dc.subject.decsneoplasias de cabeza y cuello
dc.subject.decs/radioterapia
dc.subject.decsinfecciones por Coronavirus
dc.relation.publishversionhttps://doi.org/10.1016/j.ijrobp.2020.04.016
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Thomson DJ] Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, and the Division of Cancer Sciences, The University of Manchester, UK. [Palma D] Division of Radiation Oncology, Western University, London, Canada. [Guckenberger M, Balermpas P] Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. [Beitler JJ] Department of Radiation Oncology, Emory University, Atlanta, Georgia. [Blanchard P] Department of Radiation Oncology, Gustave Roussy Cancer Center, Villejuif, France. [Giralt J] Servei d’Oncologia Radioteràpica, Vall d'Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid32302681
dc.identifier.wos000544182500004
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record